Cetuximab clinical trials
Also written Erbitux, C225 and IMC-C225.
How each study uses Cetuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Cetuximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 12 Feb 2004 · ERBITUX · BLA 125084 (FDA, Drugs@FDA)
- European Union
- 29 Jun 2004 · Erbitux · EMEA/H/C/000558 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Erbitux
- 201
In one entry with another drug
Given together, or one or the other
Biosimilars
- CDP-1
- 2
- KL 140
- 2
- CMAB009
- 2
Studies by the year they started
563 studies that test it; most in 2005 (54)
| Year | Studies |
|---|---|
| 1999 | 5 |
| 2000 | 1 |
| 2001 | 4 |
| 2002 | 1 |
| 2003 | 9 |
| 2004 | 30 |
| 2005 | 54 |
| 2006 | 41 |
| 2007 | 52 |
| 2008 | 47 |
| 2009 | 45 |
| 2010 | 39 |
| 2011 | 24 |
| 2012 | 15 |
| 2013 | 19 |
| 2014 | 12 |
| 2015 | 17 |
| 2016 | 8 |
| 2017 | 10 |
| 2018 | 17 |
| 2019 | 9 |
| 2020 | 16 |
| 2021 | 12 |
| 2022 | 7 |
| 2023 | 15 |
| 2024 | 23 |
| 2025 | 17 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 95 · Other 470
Eli Lilly and Company (30) · National Cancer Institute (NCI) (24) · M.D. Anderson Cancer Center (22) · Merck KGaA, Darmstadt, Germany (16) · Sun Yat-sen University (12) · Memorial Sloan Kettering Cancer Center (11) · Fudan University (10) · Alliance for Clinical Trials in Oncology (8)
Often tested with
Tested in the same studies.
Cisplatin (60) · Irinotecan (55) · Oxaliplatin (41) · Fluorouracil (41) · Bevacizumab (38) · Capecitabine (34) · Docetaxel (25) · Carboplatin (24)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 11 phase 3 studies under way
Cetuximab is the comparator. A study of two new drugs counts under both.
- 2Petosemtamab · Genmab · next primary completion Mar 2029
- 2Amivantamab · Janssen Research & Development, LLC · next primary completion Dec 2027
- 1Tucatinib · Seagen, a wholly owned subsidiary of Pfizer · next primary completion Dec 2027
- 1Trastuzumab · Seagen, a wholly owned subsidiary of Pfizer · next primary completion Dec 2027
- 1Ipilimumab · Bristol-Myers Squibb
- 1Nivolumab · Bristol-Myers Squibb
- 1Bevacizumab · Azienda USL Reggio Emilia - IRCCS
- 1Pembrolizumab · Merck Sharp & Dohme LLC · next primary completion Sep 2028
Reaching primary completion within a year · 15, 1 in phase 3
Studies that test Cetuximab, phase 3 first.
- Dec 2026Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal CancerPhase 3 · City Clinical Oncology Hospital No 1
- Dec 2026Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic CarcinomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell CancerPhase 2 · Wake Forest University Health Sciences
- Dec 2026ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCPhase 2 · Beijing Hospital
- Dec 2026Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerPhase 2 · Federation Francophone de Cancerologie Digestive
- Jan 2027Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal CancerPhase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Mar 2027Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCCPhase 2 · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- May 2027Combination Therapy for BRAF-V600E Metastatic CRCmPhase 2 · Vall d'Hebron Institute of Oncology
- May 2027Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell CarcinomaPhase 2 · M.D. Anderson Cancer Center
- Jun 2027A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerPhase 2 · Verastem, Inc.
Studies
Open first, then newest update. How each study uses Cetuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 565
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingPhase 3National Cancer Institute (NCI)NCT06589804Written as Cetuximab
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06997497Written as Cetuximab
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerRecruitingPhase 2Verastem, Inc.NCT07659795Written as cetuximab
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07252739Written as Cetuximab
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Cetuximab
- Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive CisplatinRecruitingPhase 3NRG OncologyNCT07441681Written as Cetuximab
- Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II StudyRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07896681Written as Cetuximab
- FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaRecruitingPhase 1National Cancer Institute (NCI)NCT06865664Written as cetuximab
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Cetuximab
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Melanoma and Skin Cancer Trials LimitedNCT06418724Written as Cetuximab
- Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07411599Written as Cetuximab
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT06369259Written as Cetuximab
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062Written as cetuximab
- Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyRecruitingPhase 1M.D. Anderson Cancer CenterNCT05985954Written as Cetuximab
- ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"RecruitingPhase 2Gruppo Oncologico Italia MeridionaleNCT07381764Written as Erbitux (Cetuximab)
- HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal CancerRecruitingPhase 1/2Haisco Pharmaceutical Group Co., Ltd.NCT07790510Written as Cetuximab (EGFR inhibitor)
- Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell CarcinomaNot yet recruitingPhase 2Peter Brett, MDNCT07733466Written as Pembrolizumab and cetuximab
- Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell CarcinomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06448026Written as Cetuximab
- ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCRecruitingPhase 2Beijing HospitalNCT06321081Written as irinotecan, cetuximab, envafolimab
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High StatusNot yet recruitingPhase 4Gruppo Oncologico del Nord-OvestNCT07094893Written as Cetuximab (EGFR inhibitor)
See all 565 studies that test Cetuximab →
Given beside what is tested · 297 — Cetuximab is usual care or a partner of the new treatment
- A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNot yet recruitingPhase 1/2Bristol-Myers SquibbNCT07939815Written as Cetuximab
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Cetuximab
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT07672483Written as Cetuximab
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerRecruitingPhase 2Verastem, Inc.NCT07644559Written as cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
- Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorRecruitingPhase 3Washington University School of MedicineNCT04966481Written as Cetuximab
- A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationRecruitingPhase 1Kestrel Therapeutics, Inc.NCT07458347Written as Cetuximab
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingPhase 2Mirati Therapeutics Inc.NCT07415031Written as Cetuximab
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Cetuximab
- A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D MutationNot yet recruitingPhase 1Boehringer IngelheimNCT07926334Written as Cetuximab
- Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06102902Written as Cetuximab
- QTX3034 in Patients With KRAS G12D MutationRecruitingPhase 1Quanta TherapeuticsNCT06227377Written as Cetuximab
- A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07915921Written as Cetuximab (CRC)
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsRecruitingPhase 1PfizerNCT07318805Written as Cetuximab
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338Written as cetuximab (Cohort C2 Only)
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCRecruitingPhase 3Johnson & Johnson Enterprise Innovation Inc.NCT04892173Written as Cetuximab
- A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid MalignanciesRecruitingPhase 1Kumquat Biosciences Inc.NCT06720987Written as Cetuximab
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07209111Written as Cetuximab
- A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) MutationNot yet recruitingPhase 1Hoffmann-La RocheNCT07905924Written as Cetuximab
- A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)RecruitingPhase 1Merck Sharp & Dohme LLCNCT07247110Written as Cetuximab
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruitingPhase 1PfizerNCT07897721Written as Cetuximab
Showing 20 of 297.
As the comparator · 52 — what is tested is compared with Cetuximab
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingPhase 3GenmabNCT07775287Written as Cetuximab
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemRecruitingPhase 2National Cancer Institute (NCI)NCT07042295Written as Cetuximab
- A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male SubjectsRecruitingPhase 1HC Biopharma Inc.NCT07813468Written as Erbitux (Cetuximab)
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingPhase 3Janssen Research & Development, LLCNCT06750094Written as Cetuximab
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06662786Written as Cetuximab
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)RecruitingPhase 3GenmabNCT07702032Written as Cetuximab
- A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaRecruitingPhase 3Corbus Pharmaceuticals Inc.NCT07768189Written as Cetuximab (EGFR inhibitor)
- Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.RecruitingPhase 3Taizhou Mabtech Pharmaceutical Co.,LtdNCT07595276Written as Erbitux®
- A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT05751512Written as Cetuximab injection
- Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT05959356Written as Cetuximab + mFOLFOX6
- Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCCRecruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT06935188Written as cetuximab
- Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRCNot yet recruitingPhase 2Fujian Cancer HospitalNCT07070713Written as FOLFOX+QL1706+Cetuximab
- Personalized, Adaptive Treatment for Locally Advanced Head and Neck CancerRecruitingPhase 1University of ChicagoNCT06005324Written as Cetuximab
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05253651Written as cetuximab
- Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedPhase 3Incyte CorporationNCT03358472Written as Cetuximab
- Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedPhase 2/3National Cancer Institute (NCI)NCT03258554Written as Cetuximab
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingPhase 3Bristol-Myers SquibbNCT04008030Written as Cetuximab
- Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaBActive, not recruitingPhase 3Azienda USL Reggio Emilia - IRCCSNCT04776655Written as Cetuximab
- A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCCCompletedPhase 1Dragonboat Biopharmaceutical Company LimitedNCT03491709Written as Cetuximab injection
- Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to ErbituxCompletedPhase 1Dragonboat Biopharmaceutical Company LimitedNCT03881787Written as Cetuximab injection
Showing 20 of 52.
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call Cetuximab · ClinicalTrials.gg INT006546
- MeSH (NLM) D000068818CetuximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PQX0D8J21JCETUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 318341Confirmed FDA, Wikidata
- Wikidata Q420296cetuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1723CetuximabOne source FDA
- DrugBank DB00002One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068818 | Cetuximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PQX0D8J21J | CETUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 318341 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420296 | cetuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1723 | Cetuximab | One source FDA |
| DrugBank | DB00002 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.